LEXINGTON, Mass.--(BUSINESS WIRE)--
Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the appointment
of Marc Becker as Chief Financial Officer, effective January 4, 2018.
Mr. Becker is a seasoned financial executive with more than 15 years of
experience in the biotechnology industry.
"We are pleased to welcome Marc to the Concert team," said Roger Tung,
Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals.
"Marc further strengthens our management team with his financial and
operational background in the industry at biotech companies across
varying sizes and stages of development. We look forward to his
contributions as we prepare to broaden our proprietary pipeline of
"I am impressed with Concert's deuterium chemistry platform approach and
excited about the potential of the Company's pipeline," said Marc
Becker. "I look forward to working with the Concert team as the Company
continues to make progress and expand its clinical pipeline and deliver
on its vision to create and develop innovative drug products that
address important patient needs."
Mr. Becker joins Concert with a strong track record of strategic and
financial experience at high-growth biotechnology companies. Prior to
joining Concert, he was Senior Vice President and Chief Financial
Officer at CRISPR Therapeutics from February 2016 to September 2017.
Prior to joining CRISPR Therapeutics, Mr. Becker served as Chief
Financial Officer and Senior Vice President of rEVO Biologics, a
commercial stage company with research, clinical, and manufacturing
operations, from January 2012 to February 2016. Prior to rEVO, Mr.
Becker spent 10 years at Genzyme, most recently serving as Finance
Director for the UK and Ireland before returning to the United States to
become the Vice President of Finance for Genzyme's Renal and Endocrine
business. Mr. Becker began his career in auditing and commercial lending
for financial services firms, KPMG and BankBoston. Mr. Becker holds a BS
from the University of Massachusetts, an MBA from Babson College and was
licensed as a CPA.
Pharmaceuticals is a clinical stage biopharmaceutical company
focused on applying its DCE
Platform® (deuterated chemical entity platform) to create novel
medicines designed to address unmet patient needs. The Company's
approach starts with approved drugs in which deuterium substitution has
the potential to enhance clinical safety, tolerability or efficacy.
Concert has a broad
pipeline of innovative medicines targeting autoimmune and
inflammatory diseases and central nervous systems (CNS) disorders. For
more information please visit www.concertpharma.com.
Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and
DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171218005062/en/
Concert Pharmaceuticals, Inc.
Kathryn Morris, 914-204-6412
Source: Concert Pharmaceuticals, Inc.
News Provided by Acquire Media